S1352
Interdisciplinary - Global health
ESTRO 2026
HW/DBStatistics/DIRAC/)3.United Nations Development Programme. Human Development Report 2023-24: Breaking the gridlock: Reimagining cooperation in a polarised world. New York: UNDP; 2024. (https://hdr.undp.org/content/human- development-report-2023-24) Keywords: oncology index, Oncology care rankings
Digital Poster 285 Global Oncology Index: Mapping Disparities in Cancer Care Across Globe Nilesh Ranjan Radiation Oncology, Health City, Guwahati, India Purpose/Objective: Cancer is a leading global health challenge, with 20 million new cases and 10 million deaths reported in 2022 (GLOBOCAN). Disparities in cancer care, driven by socioeconomic status and healthcare infrastructure, result in higher mortality in low- and middle-income countries (LMICs). The Global Oncology Index (GOI) aims to quantify these disparities and guide targeted interventions. Material/Methods: The 2025 GOI was developed for 141 countries using Cancer survival factor from GLOBOCAN 2022 and radiotherapy (RT) infrastructure from the IAEA register. The GOI formula, [(Incidence ASR – Mortality ASR) / Mortality ASR] × RT centres per million population, integrates cancer burden with treatment capacity. The GOI value is indirectly proportional to mortality while directly proportional to survival rates i.e. difference of incidence and mortality as well as cancer management related infrastructures. Correlation with Human Development Index (HDI) was assessed. Results: GOI scores ranged from 22·29 (United States) to 0·006 (Ethiopia). High-income countries, including Australia (17·69) and Japan (14·81), led rankings, while LMICs in Africa and Asia (e.g., Yemen: 0·007) ranked lowest. A significant positive correlation (r = 0·574, p < 0·001) was observed between GOI and HDI, highlighting socioeconomic influences on oncology outcomes. Conclusion: The GOI underscores global oncology disparities, emphasizing the need for enhanced cancer care infrastructure and early detection in LMICs. The strength of this index relies in its simplicity, transparency and dependency on standardized data inputs. However, in future, GOI will remain open to incorporate other standard parameters, if required, for a more holistic assessment. References: 1.Bray F, Laversanne M, Sung H. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. (https://pubmed.ncbi.nlm.nih.gov/38572751/)2.Interna tional Atomic Energy Agency. DIRAC (Directory of Radiotherapy Centres) [Internet]. Vienna: International Atomic Energy Agency; [updated 2023 Mar 9; cited 2025 Jun 18]. Available from: https://dirac.iaea.org/(https://humanhealth.iaea.org/H
Mini-Oral 415
Global Gaps in Brachytherapy Availability for Cervical Cancer: Impact on Mortality in the Era of HPV Vaccination Georgia Harris 1,2 , Dania Abu Awwad 3 , Stephen R Thompson 4,5 , Vikneswary Batumalai 6,2 , Mora Mel 7 , Yavuz Anacak 8 , Supriya Chopra 9 , Surbhi Grover 10 , Danielle Rodin 11 , Mei L Yap 6,2 1 Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, Australia. 2 Cancer Program, The George Institute for Global Health, Randwick, Australia. 3 School of Health Science, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia. 4 Department of Radiation Oncology, Prince of Wales Hospital, Randwick, Australia. 5 Randwick Clinical Campus, Faculty of Medicine, University of New South Wales, Sydney, Australia. 6 Collaboration for Cancer Outcomes, Research and Evaluation (CCORE), Ingham Institute for Applied Medical Research, Ingham Institute for Applied Medical Research, South-Western Sydney Clinical School, UNSW Sydney, Liverpool, Australia. 7 Department of Radiation Oncology, Calmette Hospital, Phnom Penh, Cambodia. 8 Department of Radiation Oncology, Ege University Faculty of Medicine and Hospital, Izmir, Turkey. 9 Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institution, Navi Mumbai, India. 10 Department of Radiation Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA. 11 Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Department of Radiation Oncology, University of Toronto, Toronto, Canada Purpose/Objective: Cervical cancer is the fourth most common cancer in women, with disproportionate incidence and mortality in low- and middle-income countries (LMICs). Brachytherapy (BT) is an essential component of curative radiation therapy for locally advanced cervical cancer, yet global access is inadequate. We used a country income-group adjusted model to estimate the current and projected availability of BT machines for cervical cancer to evaluate the impact of BT deficits on cervical cancer mortality through 2045. Material/Methods:
Made with FlippingBook - Share PDF online